

**L.N. 199 of 2022**

**Dangerous Drugs Ordinance (Amendment of First Schedule) Order 2022**

(Made by the Chief Executive under section 50(1) of the Dangerous Drugs Ordinance (Cap. 134) after consultation with the Executive Council)

**1. Commencement**

- (1) Subject to subsection (2), this Order comes into operation on 16 December 2022.
- (2) Section 3(2) comes into operation on 1 February 2023.

**2. Dangerous Drugs Ordinance amended**

The Dangerous Drugs Ordinance (Cap. 134) is amended as set out in section 3.

**3. First Schedule amended**

- (1) First Schedule, Part I, paragraph 1(a), after item “Bromazepam (溴西洋)”—

**Add**

“Brorphine (溴啡)”.

- (2) First Schedule, Part I, paragraph 1(a), after item “Camazepam (卡馬西洋)”—

**Add**

“Cannabidiol (大麻二酚)”.

- (3) First Schedule, Part I, paragraph 1(a), item “Clobazam (氯巴詹)”—

**Repeal**

“詹”

**Substitute**

“占”.

- (4) First Schedule, Part I, paragraph 1(a), after item “Clonazepam (氯硝西洋)”—

**Add**

“Clonazolam (氯氮唑侖)”.

- (5) First Schedule, Part I, paragraph 1(a), after item “Diazepam (安定)”—

**Add**

“Diclazepam (二氯西洋)”.

- (6) First Schedule, Part I, paragraph 1(a), item “Difenoxin (氟苯哌酸氰)”—

**Repeal**

“酸氰”

**Substitute**

“酸”.

- (7) First Schedule, Part I, paragraph 1(a), after item “Dioxaphetyl butyrate (嗎苯丁酯)”—

**Add**

“Diphenidine (二苯基乙基哌啶)”.

- (8) First Schedule, Part I, paragraph 1(a), after item “Flualprazolam (氟阿普唑侖)”—

**Add**

“Flubromazolam (氟溴唑侖)”.

- (9) First Schedule, Part I, paragraph 1(a), after item “Isomethadone (異美沙酮)”—

**Add**

“Isotonitazene (異硝氮烯)”.

- (10) First Schedule, Part I, paragraph 1(a), after item “Methyl N- {[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl}-3-methylvalinate (N- {[1-(環己基甲基)-1H-吲哚-3-基]羰基}-3-甲基纈氨酸甲酯)”—

**Add**

“Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (3,3- 二甲基 -2-(1-( 戊 -4- 烯 -1- 基 )-1H- 吲唑 -3- 甲酰基 ) 丁酸甲酯)”.

- (11) First Schedule, Part I, paragraph 1(a), after item “Methyl phenidate (哌醋甲酯)”—

**Add**

“Metonitazene (甲硝苯)”.

- (12) First Schedule, Part I, paragraph 1(a)—

**Repeal item “Nicocodine (6- 烟鹼可待因 ( 菸鹼可待因 ))”**

**Substitute**

“Nicocodine (6-nicocodine) ( 菸鹼可待因 (6- 煙鹼可待因 ))”.

- (13) First Schedule, Part I, paragraph 1(a), item “Nicomorphine (3,6-dinicotinoyl-morphine) (3, 6 二烟酰嗎啡 ( 菸鹼嗎啡 ))”—

**Repeal**

“3, 6 二烟”

**Substitute**

“3,6 二煙”.

- (14) First Schedule, Part I, paragraph 1(a), item “Zipeprol (雙苯呱丙醇)”—

**Repeal**

“呱”

**Substitute**

“哌”.

- (15) First Schedule, Part I, paragraph 1(a), after item “4-Methylthioamphetamine (4-甲硫苯丙胺(4-甲硫安非他明))”—

**Add**

“5-Pentyl-2-(2-phenylpropan-2-yl)-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one (5-戊基-2-(2-苯基丙-2-基)-2,5-二氢-1H-吡啶[4,3-b]吲哚-1-酮)”.

- (16) First Schedule, Part III, paragraph 19, item “Ethylmorphine (3-ethylmorphine) (乙基嗎啡)”, after “乙基嗎啡”—

**Add**

“(3-乙基嗎啡)”.

- (17) First Schedule, Part III, paragraph 19, item “Nicocodine (菸鹼可待因)”—

**Repeal**

“(菸鹼可待因)”

**Substitute**

“(6-nicocodine) (菸鹼可待因 (6-煙鹼可待因))”.

John KC LEE  
Chief Executive

14 October 2022

### **Explanatory Note**

This Order amends Part I of the First Schedule to the Dangerous Drugs Ordinance (Cap. 134) to—

- (a) bring 9 substances into the regulatory regime under the Ordinance as from 16 December 2022; and
  - (b) bring Cannabidiol into the regulatory regime under the Ordinance as from 1 February 2023.
2. The Order also amends Parts I and III of that Schedule to make technical amendments in respect of the names of substances specified in 7 items in those Parts.